MedTrace Logo

Analysis of Sleep Study Data to Assess Depressive Burden

NCT04232267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 329

Last updated 2023-12-21

No results posted yet for this study

Summary

This study evaluates the effectiveness of the MEB-001 device in assessing physiological parameters that provide a clinically significant depressive burden screener. This study uses objective physiological markers from MEB-001 to estimate the clinically significant depressive burden as subjectively reported by the subject with the Beck Depression Inventory - II (BDI-II).

Conditions

  • Sleep Disorder
  • Depressive; Behavioral Disorder
  • Mood Disorders

Interventions

DEVICE

MEB-001

Software medical device used to aid in the screening of patients with potential depressive burden symptoms.

Sponsors & Collaborators

  • Medibio Limited

    lead INDUSTRY

Principal Investigators

  • Melissa Bruner · Medibio Limited

  • Archie Defillo, MD · Medibio Limited

  • Archie Defillo, MD · Medibio Limited

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2022-03-01
Completion
2022-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232267 on ClinicalTrials.gov